
https://www.science.org/content/blog-post/amgen-cuts-harder
# Amgen Cuts Harder (October 2014)

## 1. SUMMARY
The article reports on Amgen's announcement that it would increase its workforce reduction from an initially planned 12-15% to 20%, representing over a thousand additional layoffs beyond the previously announced restructuring. These cuts followed an earlier round of site closures that had already reduced Amgen's physical footprint. Despite the significant job losses, the article notes that the company's stock price rose following the announcement, and that Amgen was also implementing share buybacks.

## 2. HISTORY
Following the 2014 restructuring, Amgen continued to evolve its business model toward more specialized therapeutic areas while maintaining profitability. The company shifted focus toward oncology, inflammation, and rare diseases, while reducing its traditional emphasis on broader-market drugs. Amgen launched several successful drugs in subsequent years, including Repatha (evolocumab) for cholesterol management in 2015 and Aimovig (erenumab) for migraine prevention in 2018. The company made significant acquisitions, notably purchasing Celgene's Otezla (apremilast) for $13.4 billion in 2019 to strengthen its inflammation portfolio. Amgen also expanded its biosimilars business and maintained a strong R&D pipeline in oncology. The company's stock appreciated over time, and it continued to return capital to shareholders through dividends and buybacks. The restructuring appears to have been part of a strategic realignment toward higher-value, specialized therapies.

## 3. PREDICTIONS
- The article did not contain specific forward-looking predictions about drug development outcomes, market dynamics, or policy changes
- The piece focused on immediate restructuring news rather than forecasting future developments
- No particular therapeutic areas, drug candidates, or business strategies were predicted for future success or failure

## 4. INTEREST
Rating: **4/10**
This article primarily reports routine corporate restructuring news rather than examining substantive scientific or technological developments in biotechnology. While restructuring announcements can signal broader industry trends, the short piece lacks the depth and forward-looking analysis that would provide lasting insight into major biotech developments.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20141028-amgen-cuts-harder.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_